← brief for 2026-09-21 · Slowing decline

Disproportionality analysis of acute kidney injury and nephritis signals for nivolumab plus relatlimab (Opdualag), 2022-2026

Preprint No results yet Not peer reviewed

Key takeaways

This study looks at safety reports for a cancer drug called Opdualag. It checks if the drug causes kidney injury or inflammation. The data comes from a large database of side effect reports. It is a preprint, so it has not passed peer review yet. There are no final trial results.

Who did this work

Sisi Wan (Sun Yat-sen University) · Lejia Xu (Sun Yat-sen University)

Source

Preprint · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-09-20
https://doi.org/10.22541/authorea.15009096/v1